Patients with Inflammatory Bowel Disease (IBD) are at Increased Risk for Colorectal Cancer and Early Dysplasia
About this study
The purpose of the study is to:
- Map and compare the neoplasia-associated epigenetic field in IBD-CRN, sporadic CRN and controls.
- Measure sensitivity of DNA methylation for the detection of synchronous IBD-CRN as a complement or alternative to histologic diagnosis of dysplasia on random biopsies.
- Measure the density and types of lymphocytes infiltrating IBD-CRN tumors, sporadic tumors and the epigenetic field.
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.See eligibility criteria
Subject population: Patients with chronic colitis (ulcerative colitis or Crohn’s colitis) who have undergone surgery to treat medically refractory disease or disease complications, including advanced pre-cancer or cancer of the colorectum.
Patients will be adults having surgery at Mayo Clinic with chronic inflammatory bowel disease of the colon.
Pre-operative chemotherapy or radiation;
Participating Mayo Clinic locations
Study statuses change often. Please contact us for help.
|Mayo Clinic Location
Mayo Clinic principal investigator
John Kisiel, M.D.
Open for enrollment
John Kisiel M.D.